New pill for advanced cancers enters first human tests

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects voluntarily joined the study, signed informed consent form, and with good compliance. * ≥18 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-1; at least 3 months expected survival period. * At least 1 measurable lesion for efficacy evaluation. * The function of main organs is normal. * Women of childbearing age should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study, and have a negative serum or urine pregnancy test within 7 days before enrollment in the study; Men should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study period. Exclusion Criteria: * Individuals who have undergone major surgical treatment, significant traumatic injury, or major surgery during the expected study treatment period within 4 weeks prior to the first medication (excluding surgeries specified in the protocol), or have long-term untreated wounds or fractures. (Major surgery is defined as surgery at level 3 or above in the National Surgical Classification Catalogue 2022 edition); * Subjects who experience any bleeding or bleeding events ≥ CTC AE grade 3 within 4 weeks prior to the first administration. * Active syphilis infected individuals in need of treatment * Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders; * Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation; * History of hepatic encephalopathy; * Active or uncontrolled infections (≥ CTC AE level 2 infection); * Patients with renal failure requiring hemodialysis or peritoneal dialysis; * History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases; * Individuals with epilepsy who require treatment; * Poor control of diabetes (assessed by the investigator); * Known to be allergic to research drugs or excipients; * Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first medication; * According to the researcher's judgment, there is a situation that seriously endangers the safety of the subjects or affects their ability to complete the study.